申请人:Nogra Pharma Limited
公开号:US20160194303A1
公开(公告)日:2016-07-07
The present disclosure is directed in part to heterocycles, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.